Medicus Pharma explores novel treatment innovations for prostate, skin cancers

The company said, “November is Men’s Health Awareness Month, a time to spotlight the latest medical breakthroughs that may transform how we detect and treat cancer- especially prostate and skin cancer, which are among the most common cancers affecting men. In advanced prostate cancer, lifelong treatment modalities are making a difference, yet challenges remain for patients with a high cardiovascular risk profile linked to hormone deprivation therapies.” “While hormone deprivation therapy has long been the standard for advanced prostate cancer, most of the drugs in this category can raise cardiovascular risks,” explained Dr. Raza Bokhari, Executive Chairman & CEO. “Medicus Pharma (MDCX) is developing next-generation hormone deprivation therapies for advanced stage prostate cancer that may protect the heart while effectively controlling the cancer.”